Digestive Diseases and Sciences

, Volume 64, Issue 12, pp 3568–3578 | Cite as

Eosinophilic Esophagitis Is Rarely Continually Symptomatic 10 Years After an Initial Treatment Course in Adults

  • A. J. Podboy
  • C. Lavey
  • K. Mara
  • D. Geno
  • S. Khana
  • K. Ravi
  • D. Katzka
  • J. AlexanderEmail author
Original Article



Despite its initial description over 25 years ago, there is little known about the course of eosinophilic esophagitis (EoE) after an initial course of medical or dietary treatment. We aim to assess the long-term symptomology and quality of life (QoL) metrics in patients 10 years after initial treatment for eosinophilic esophagitis.


Inclusion criteria: single center study of EoE patients diagnosed over 10 years ago with completion of an 18-question structured telephone interview. A cohort of patient’s prospectively underwent an esophageal barium exam, esophageal sponge cytology, and evaluation by a esophagologist at greater than 10 years’ time since original diagnosis.


A total of 54 patients were included in the study. The average age at follow-up was 55.0, with the majority male (64.8%). At the original diagnosis, 62.9% and 37.0% were initially treated with topical steroids and a proton pump inhibitor (PPI), respectively,compared to 59.3% and 7.4% after 10 years, and 7.4% of patients reported a history of dilatations. Only 11.8% noted avoidance of trigger foods, with 62.7% noting an unlimited diet without caution. QoL decrease secondary to EoE was noted to be trivial to minimal in 56.9% of patients, mild in 19.6%, moderate in 15.7% and severe in 7.8%. In the prospective follow-up cohort, the results of telephone survey results matched the direct physician-obtained interview in 88% of cases.


Ten years after diagnosis, treated EoE is rarely continually symptomatic, requires mainly PPI-based therapies and is associated with a minimal decrease in QoL scores.


Eosinophilic esophagitis Proton pump inhibitors Gastroesophageal reflux Quality of life 



Eosinophilic esophagitis


Gastroesophageal reflux disease


High powered field


Proton pump inhibitor


Proton pump inhibitor responsive esophageal eosinophilia



Study supported by an unrestricted grant from Mayo Clinic Rochester Gastroenterology.

Author’s contribution

Dr. Podboy is a Gastroenterology and Hepatology fellow at Stanford University Hospital in Stanford, California. He was instrumental in the design and conduct of the study, data collection, and writing of the manuscript. Crystal Lavey is a research assistant in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. She assisted in the collection of the data. Debra Geno is a research assistant in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. She assisted in the collection of the data. Kristin Mara is a statistician in the Department of Health Sciences Research and assisted in the statistical methods, analysis and critical appraisal of the manuscript. Dr. Kanna is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in the critical appraisal of the manuscript. Dr. Katzka is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in data interpretation, writing and critical appraisal of the manuscript. Dr. Ravi is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in the critical appraisal of the manuscript. Dr. Alexander is a gastroenterologist in the department of Gastroenterology and Hepatology at the Mayo Clinic Rochester. He was instrumental in the design and conduct of the study, data collection, critical appraisal and writing of the manuscript.

Compliance with Ethical Standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Statement on the welfare of animals

This article does not contain any studies with animals performed by any of the authors.

Supplementary material

10620_2019_5636_MOESM1_ESM.doc (64 kb)
Supplementary material 1 (DOC 64 kb)
10620_2019_5636_MOESM2_ESM.docx (17 kb)
Supplementary material 2 (DOCX 17 kb)


  1. 1.
    Dellon ES, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE). Am J Gastroenterol. 2013;108:679.CrossRefGoogle Scholar
  2. 2.
    Liacouras CA, Furuta GT, Hirano I, et al. Eosinophilic esophagitis: updated consensus recommendations for children and adults. J Allergy Clin Immunol. 2011;128:3.CrossRefGoogle Scholar
  3. 3.
    Prasad GA, Talley NJ, Romero Y, et al. Prevalence and predictive factors of eosinophilic esophagitis in patients presenting with dysphagia: a prospective study. Am J Gastroenterol. 2007;102:2627–2632.CrossRefGoogle Scholar
  4. 4.
    Mackenzie SH, Go M, Chadwick B, et al. Clinical trial: eosinophilic esophagitis in patients presenting with dysphagia: a prospective analysis. Aliment Pharmacol Ter. 2008;28:1140–1146.CrossRefGoogle Scholar
  5. 5.
    Straumann A. The natural history and complications of eosinophilic esophagitis. Thorac Surg Clin. 2011;21:575–587.CrossRefGoogle Scholar
  6. 6.
    Podboy A, Katzka DA, Enders F, et al. Oesophageal narrowing on barium oesophagram is more common in adult patients with eosinophilic oesophagitis than PPI-responsive oesophageal eosinophilia. Aliment Pharmacol Therap. 2016;. Scholar
  7. 7.
    Schoepfer AM, Safroneeva E, Bussmann C, et al. Delay in diagnosis of eosinophilic esophagitis increases risk for stricture formation in a time-dependent manner. Gastroenterology. 2013;145:1230e2–1236e2.CrossRefGoogle Scholar
  8. 8.
    Dellon ES, Kim HP, Sperry SL, Rybnicek DA, Woosley JT, Shaheen NJ. A phenotypic analysis shows tha eosinophilic esophagitis is a progressive fibrostenotic disease. Gastrointest Endosc. 2014;79:577e4–585e4.CrossRefGoogle Scholar
  9. 9.
    Straumann A, Spichtin H-P, Grize L, et al. Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology. 2003;125:1660–1669.CrossRefGoogle Scholar
  10. 10.
    Warners M, Nijhuis RAO, De Wijkerslooth LR, et al. The natural course of eosinophilic esophagitis and long-term consequences of undiagnosed disease in a large cohort. Am J Gastroenterol. 2018;113:836–844.CrossRefGoogle Scholar
  11. 11.
    Ronkainen J, Talley NJ, Aro P, et al. Prevalence of oesophageal eosinophils and eosinophilic oesophagitis in adults: the population-based Kalixanda study. Gut. 2007;56:615–620. Scholar
  12. 12.
    Mansoor E, Cooper GS. The 2010–2015 prevalence of eosinophilic esophagitis in the United States: a population-based study. Dig Dis Sci. 2016;61:2928–2934. Scholar
  13. 13.
    Dellon ES. Epidemiology of eosinophilic esophagitis. Gastroenterol Clin N Am. 2014;43:201–218. Scholar
  14. 14.
    Menard-Katcher P, Marks KL, Liacouras CA, et al. The natural history of eosinophilic oesophagitis in the transition from childhood to adulthood. Aliment Pharmacol Ther. 2013;37:114–121.CrossRefGoogle Scholar
  15. 15.
    Dellon ES, Erichsen R, Baron JA, et al. The increasing incidence and prevalence of eosinophilic oesophagitis outpaces changes in endoscopic and biopsy practice: national population-based estimates from Denmark. Aliment Pharmacol Ther. 2015;41:662–670.CrossRefGoogle Scholar
  16. 16.
    Hruz P, Straumann A, Bussmann C, et al. Escalating incidence of eosinophilic esophagitis: a 20-year prospective, population-based study in Olten County, Switzerland. J Allergy Clin Immunol. 2011;128:1349–1350.CrossRefGoogle Scholar
  17. 17.
    Straumann A, Simon HU. Eosinophilic esophagitis: escalating epidemiology? J Allergy Clin Immunol. 2005;115:418–419.CrossRefGoogle Scholar
  18. 18.
    Prasad GA, Alexander JA, Schleck CD, et al. Epidemiology of eosinophilic esophagitis over three decades in Olmsted County, Minnesota. Clin Gastroenterol Hepatol. 2009;7:1055–1061.CrossRefGoogle Scholar
  19. 19.
    Whitney-Miller CL, Katzka D, Furth EE. Eosinophilic esophagitis: a retrospective review of esophageal biopsy specimens from 1992 to 2004 at an adult academic medical center. Am J Clin Pathol. 2009;131:788–792.CrossRefGoogle Scholar
  20. 20.
    Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and risk of chronic kidney disease. JAMA Intern Med. 2016;176:238–246. Scholar
  21. 21.
    Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementiaa pharmacoepidemiological claims data analysis. JAMA Neurol. 2016;73:410–416. Scholar
  22. 22.
    Yepuri G, Sukhovershin R, Nazari-Shafti TZ, Petrascheck M, Ghebre YT, Cooke JP. Proton pump inhibitors accelerate endothelial senescence. Circ Res. 2016;118:e36–e42. Scholar
  23. 23.
    Furuta GT, Liacouras CA, Collins MH, et al. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology. 2007;133:1342–1363.CrossRefGoogle Scholar
  24. 24.
    Grudell ABM, Alexander JA, Enders FB, et al. Validation of the Mayo Dysphagia Questionnaire. Dis Esophagus. 2007;20:202–205. Scholar
  25. 25.
    Bohm M, Jacobs JW, Gupta A, Gupta S, Wo JM. Most children with eosinophilic esophagitis have a favorable outcome as young adults. Dis Esophagus. 2017;30:1–6. Scholar
  26. 26.
    Van Rhijn BD, Weijenborg PW, Verheij J, et al. Proton pump inhibitors partially restore mucosal integrity in patients with proton pump inhibitor-responsive esophageal eosinophilia but not eosinophilic esophagitis. Clin Gastroenterol Hepatol. 2014;12:1815–2300.CrossRefGoogle Scholar
  27. 27.
    Molina-Infante J, Rivas MD, Hernandez‐Alonso M, et al. Proton pump inhibitor-responsive oesophageal eosinophilia correlates with downregulation of eotaxin-3 and Th2 cytokines overexpression. Aliment Pharmacol Ther. 2014;40:955–965.CrossRefGoogle Scholar
  28. 28.
    Moawad FJ, Wells JM, Johnson RL, et al. Comparison of eotaxin-3 biomarker in patients with eosinophilic oesophagitis, proton pump inhibitor-responsive oesophageal eosinophilia and gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2015;42:231–238.CrossRefGoogle Scholar
  29. 29.
    Kedika RR, Souza RF, Spechler SJ. Potential anti-inflammatory effects of proton pump inhibitors: a review and discussion of the clinical implications. Dig Dis Sci. 2009;54:2312–2317. Scholar
  30. 30.
    Safroneeva E, Straumann A, Coslovsky M, et al. Symptoms have modest accuracy in detecting endoscopic and histologic remission in adults with eosinophilic esophagitis. Gastroenterology. 2016;150:581–5900000.CrossRefGoogle Scholar
  31. 31.
    Krishna SG, Kakati BR, Olden KW, et al. Treatment of eosinophilic esophagitis: Is oral viscous budesonide superior to swallowed fluticasone spray? Gastroenterol Hepatol. 2011;7:55–59.Google Scholar
  32. 32.
    Albert D, Heifert TA, Min SB, et al. Comparisons of fluticasone to budesonide in the treatment of eosinophilic esophagitis. Dig Dis Sci. (Epub ahead of print). Scholar
  33. 33.
    Lipka S, Kumar A, Miladinovic B, et al. Systematic review with network meta-analysis: comparative effectiveness of topical steroids vs. PPIs for the treatment of the spectrum of eosinophilic oesophagitis. Aliment Pharmacol Ther. 2016;43:663–673.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • A. J. Podboy
    • 1
  • C. Lavey
    • 2
  • K. Mara
    • 3
  • D. Geno
    • 2
  • S. Khana
    • 2
  • K. Ravi
    • 2
  • D. Katzka
    • 2
  • J. Alexander
    • 2
    Email author
  1. 1.Division of Gastroenterology and HepatologyStanford University School of MedicineStanfordUSA
  2. 2.Division of GastroenterologyMayo ClinicRochesterUSA
  3. 3.Department of Health Sciences ResearchMayo ClinicRochesterUSA

Personalised recommendations